Stay updated on Pembrolizumab Combo in Resectable NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page
- CheckyesterdayChange DetectedThe clinical trial is now listed as completed and no longer seeking participants, with its completion date recorded as actual. The record also reflects an updated posting date and verification date.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe clinical trial record for the pembrolizumab and chemotherapy study in resectable non-small cell lung cancer is available, with its study design, eligibility criteria, outcomes, locations, publications, and supporting documents.SummaryDifference100%

- Check22 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0. The study page remains inaccessible and shows a 403 Forbidden error.SummaryDifference0.2%

- Check29 days agoChange DetectedA site-wide NIH notice announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check36 days agoChange DetectedThe footer now displays ClinicalTrials.gov revision v3.7.2 instead of v3.7.1.SummaryDifference0.2%

- Check43 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1; the study record still displays a 403 error.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab Combo in Resectable NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.